The analysis of the in vivo levels of MIF expression in 166 gliomas and 23 normal control brains by immunohistochemistry has shown that MIF immunoreactivity was increased in WHO grade II gliomas and increased significantly in higher tumour grades (III-IV) [83]. Here, MIF is linked to glioma.